Latest Anti-diabetic drugs Stories
- Results support resubmission of U.S.
The $1.3 million in punitive damages is in addition to a $2.3 million award to the plaintiff, who alleges that Actos caused him to develop bladder cancer.
NORWALK, Conn., Feb.
CARLSBAD, Calif., Feb. 3, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Jan.
JERUSALEM, January 16, 2015 /PRNewswire/ -- Oramed Pharmaceuticals Inc.
PLAINSBORO, N.J., Dec.
Hundreds of Byetta lawsuits and other product liability claims involving incretin mimetic diabetes drugs are currently pending in the federal litigation underway in California. New
DALLAS, December 10, 2014 /PRNewswire/ -- ReportsnReports.com adds Type 2 Diabetes Therapeutics in Asia-Pacific Markets to 2020 - Increasing Uptake of Novel Drug Classes
The Firm is evaluating Byetta lawsuits and other product liability claims on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis or thyroid cancer caused by incretin
- A bereavement by loss of parents or children; the state of being orbate; orbation.